{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-023853","form_type":"8-K","ticker":"LFMD","cik":"0000948320","company_name":"LifeMD, Inc.","filed_at":"2025-11-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.697813+00:00","generated_at":"2026-05-16T19:36:16.526970+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"LifeMD Q3 revenue $60.2M (+13%), adj EBITDA $5.1M; paid off debt, sold WorkSimpli","bullets":["Total revenue $60.2M (+13% YoY); adjusted EBITDA $5.1M (+20% YoY).","Telehealth revenue $47.3M (+18% YoY); telehealth adjusted EBITDA $2.9M (+30% YoY).","Paid off all outstanding debt in Q3; divested majority stake in WorkSimpli after quarter end.","Pennsylvania 503-A compounding pharmacy approved; licensed in 14 states, pursuing 50-state license.","RexMD added nearly 10,000 net new subscribers; strong early traction in behavioral, women's, men's health."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-023853","json":"https://secwatch.observer/filing/0001493152-25-023853.json","markdown":"https://secwatch.observer/filing/0001493152-25-023853.md","text":"https://secwatch.observer/filing/0001493152-25-023853.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/948320/000149315225023853/0001493152-25-023853-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/948320/000149315225023853/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:36:16.526970+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}